(Q40790546)

English

Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level (English)

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

author name string

T Sano

1

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

N Saijo

2

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

Y Sasaki

3

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

T Shinkai

4

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

K Eguchi

5

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

T Tamura

6

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

M Sakurai

7

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

H Takahashi

8

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

H Nakano

9

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

K Nakagawa

10

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

publication date

1 January 1988

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

number of pages

13

1 reference

based on heuristic

inferred from page(s)

Japanese Journal of Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

79

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

1

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

131-143

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

22 June 2018

T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

22 June 2018

Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

22 June 2018

Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

22 June 2018

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

22 June 2018

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

22 June 2018

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

22 June 2018

Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

22 June 2018

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

22 June 2018

Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

22 June 2018

The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

22 June 2018

Reduction of pulmonary metastases of B16 melanoma by human recombinant interleukin 2 and lymphokine-activated killer cells in immunosuppressed C57BL/6 mice receiving anticancer agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

22 June 2018

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

22 June 2018

T cell growth factor: parameters of production and a quantitative microassay for activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

22 June 2018

In vivo administration of purified Jurkat-derived interleukin 2 in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5907760

19 August 2018

Interleukin-2 augments natural killer cell activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.1988.TB00020.X

21 January 2018

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

https://pubmed.ncbi.nlm.nih.gov/3128501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of cytotoxicity of freshly obtained lymphocytes and of lymphocytes activated with recombinant interleukin II (rIL-2) against lung cancer cell lines by human tumor clonogenic assay (HTCA)

1 reference

https://pubmed.ncbi.nlm.nih.gov/3128501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization

1 reference

https://pubmed.ncbi.nlm.nih.gov/3128501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/3128501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lysis of spontaneous murine breast tumors by human interleukin 2-stimulated syngeneic T-lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/3128501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (r

1 reference

https://pubmed.ncbi.nlm.nih.gov/3128501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets

1 reference

https://pubmed.ncbi.nlm.nih.gov/3128501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/3128501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/3128501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/3128501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1349-7006.1988.TB00020.X

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 June 2018

http://europepmc.org/abstract/PMC/5907760

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40790546&oldid=1907396211"